Elizabeth A. Grimm

18.3k total citations · 3 hit papers
236 papers, 13.3k citations indexed

About

Elizabeth A. Grimm is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Elizabeth A. Grimm has authored 236 papers receiving a total of 13.3k indexed citations (citations by other indexed papers that have themselves been cited), including 141 papers in Immunology, 100 papers in Oncology and 79 papers in Molecular Biology. Recurrent topics in Elizabeth A. Grimm's work include Immunotherapy and Immune Responses (71 papers), Immune Cell Function and Interaction (60 papers) and T-cell and B-cell Immunology (28 papers). Elizabeth A. Grimm is often cited by papers focused on Immunotherapy and Immune Responses (71 papers), Immune Cell Function and Interaction (60 papers) and T-cell and B-cell Immunology (28 papers). Elizabeth A. Grimm collaborates with scholars based in United States, Australia and Japan. Elizabeth A. Grimm's co-authors include Steven A. Rosenberg, A Mazumder, Laurie B. Owen‐Schaub, Sühendan Ekmekçioglu, Benjamin Bonavida, Sunil Chada, Debra J. Wilson, Julie A. Ellerhorst, Jack A. Roth and William L. Crump and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Elizabeth A. Grimm

232 papers receiving 12.8k citations

Hit Papers

3 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

1982 1.8k citations Elizabeth A. Grimm et al. profile →
Biological Activity of Recombinant Human Interleukin-2 Produced in Escherichia coli

1984 525 citations Elizabeth A. Grimm et al. profile →
Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor.

1981 425 citations Elizabeth A. Grimm et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Elizabeth A. Grimm United States	59	7.2k	5.3k	4.2k	1.8k	1.1k	236	13.3k
Kazuo Sugamura Japan	78	12.2k 1.7×	4.0k 0.8×	4.9k 1.2×	1.8k 1.0×	1.5k 1.4×	304	20.8k
Michael A. Palladino United States	63	7.8k 1.1×	3.5k 0.7×	7.4k 1.8×	1.1k 0.6×	1.7k 1.5×	218	18.4k
James E. Talmadge United States	52	4.9k 0.7×	4.2k 0.8×	4.1k 1.0×	672 0.4×	1.6k 1.5×	251	11.7k
Ena Wang United States	67	7.2k 1.0×	6.3k 1.2×	5.4k 1.3×	1.4k 0.8×	2.0k 1.8×	260	14.2k
Keith L. Knutson United States	55	6.7k 0.9×	6.4k 1.2×	4.7k 1.1×	784 0.4×	1.7k 1.5×	187	14.3k
Robert H. Wiltrout United States	59	6.1k 0.8×	3.4k 0.6×	3.1k 0.7×	715 0.4×	1.1k 1.0×	183	10.3k
Barbara Seliger Germany	65	8.1k 1.1×	6.3k 1.2×	5.3k 1.3×	896 0.5×	1.8k 1.6×	362	15.2k
Piero Musiani Italy	52	5.0k 0.7×	4.1k 0.8×	5.8k 1.4×	1.1k 0.6×	3.9k 3.5×	212	12.2k
Francesco Colotta Italy	52	6.0k 0.8×	3.6k 0.7×	4.0k 1.0×	656 0.4×	1.5k 1.4×	138	12.9k
William L. Farrar United States	71	5.7k 0.8×	4.7k 0.9×	6.8k 1.6×	1.1k 0.6×	2.2k 2.0×	212	15.5k

Countries citing papers authored by Elizabeth A. Grimm

Since Specialization

Citations

This map shows the geographic impact of Elizabeth A. Grimm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elizabeth A. Grimm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elizabeth A. Grimm more than expected).

Fields of papers citing papers by Elizabeth A. Grimm

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elizabeth A. Grimm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elizabeth A. Grimm. The network helps show where Elizabeth A. Grimm may publish in the future.

Co-authorship network of co-authors of Elizabeth A. Grimm

This figure shows the co-authorship network connecting the top 25 collaborators of Elizabeth A. Grimm. A scholar is included among the top collaborators of Elizabeth A. Grimm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elizabeth A. Grimm. Elizabeth A. Grimm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Meng, Fancui, et al.. (2025). S-Nitrosylation of p53 in Melanoma Cells Under Nitrosative Stress. International Journal of Molecular Sciences. 26(13). 6512–6512. 1 indexed citations

Fukuda, Yasunari, Matías A. Bustos, Jason Roszik, et al.. (2022). Interplay between soluble CD74 and macrophage-migration inhibitory factor drives tumor growth and influences patient survival in melanoma. Cell Death and Disease. 13(2). 117–117. 35 indexed citations

Chattopadhyay, Chandrani, Rajat Bhattacharya, Jason Roszik, et al.. (2022). Targeting IRS-1/2 in Uveal Melanoma Inhibits In Vitro Cell Growth, Survival and Migration, and In Vivo Tumor Growth. Cancers. 14(24). 6247–6247. 6 indexed citations

Kim, Sun‐Hee, et al.. (2018). Mitochondrial dynamic alterations regulate melanoma cell progression. Journal of Cellular Biochemistry. 120(2). 2098–2108. 21 indexed citations

Qin, Yong, Jason Roszik, Chandrani Chattopadhyay, et al.. (2016). Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma. Molecular Cancer Therapeutics. 15(10). 2442–2454. 41 indexed citations

Wang, Lie, Chunying Li, Ping Xiong, et al.. (2014). 4-Nitroquinoline-1-oxide-induced mutagen sensitivity and risk of cutaneous melanoma. Melanoma Research. 26(2). 181–187. 7 indexed citations

López-Rivera, Esther, Padmini Jayaraman, Falguni Parikh, et al.. (2014). Inducible Nitric Oxide Synthase Drives mTOR Pathway Activation and Proliferation of Human Melanoma by Reversible Nitrosylation of TSC2. Cancer Research. 74(4). 1067–1078. 80 indexed citations

Chattopadhyay, Chandrani, Scott E. Woodman, Bita Esmaeli, & Elizabeth A. Grimm. (2012). Targeting IGF-1R In Uveal Melanoma Cells. Investigative Ophthalmology & Visual Science. 53(14). 3396–3396. 1 indexed citations

Qin, Yong, Sühendan Ekmekçioglu, Ping Liu, et al.. (2011). Constitutive Aberrant Endogenous Interleukin-1 Facilitates Inflammation and Growth in Human Melanoma. Molecular Cancer Research. 9(11). 1537–1550. 73 indexed citations

10.

Sikora, Andrew G., Alexander Gelbard, Michael A. Davies, et al.. (2010). Targeted Inhibition of Inducible Nitric Oxide Synthase Inhibits Growth of Human Melanoma In vivo and Synergizes with Chemotherapy. Clinical Cancer Research. 16(6). 1834–1844. 107 indexed citations

11.

Ellerhorst, Julie A., Victoria R. Greene, Sühendan Ekmekçioglu, et al.. (2010). Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma. Clinical Cancer Research. 17(2). 229–235. 187 indexed citations

12.

Li, Chunying, Zhibin Hu, Zhensheng Liu, et al.. (2007). Polymorphisms of the neuronal and inducible nitric oxide synthase genes and the risk of cutaneous melanoma. Cancer. 109(8). 1570–1578. 19 indexed citations

13.

Mumm, John B., Sühendan Ekmekçioglu, Nancy Poı̀ndexter, Sunil Chada, & Elizabeth A. Grimm. (2006). Soluble Human MDA-7/IL-24: Characterization of the Molecular Form(s) Inhibiting Tumor Growth and Stimulating Monocytes. Journal of Interferon & Cytokine Research. 26(12). 877–886. 17 indexed citations

14.

Ellerhorst, Julie A., William H. Hildebrand, J.W. Cavett, et al.. (2004). HLA class II haplotypes predict favorable outcomes for patients with metastatic RCC. Der Urologe. 43(S3). 137–137. 1 indexed citations

15.

Chada, Sunil, Abner M. Mhashilkar, Rajagopal Ramesh, et al.. (2004). Bystander activity of Ad-mda7: Human MDA-7 protein kills melanoma cells via an IL-20 receptor-dependent but STAT3-independent mechanism. Molecular Therapy. 10(6). 1085–1095. 89 indexed citations

16.

Rodriguez, Maria Alma, Fernando Cabanillas, Nam H. Dang, et al.. (2004). Recovery of natural killer cell counts after one course of CHOP chemotherapy is diminished in patients older than 60 compared to patients younger than 60.. Cancer Research. 64. 507–507. 2 indexed citations

17.

Caudell, Eva G., John B. Mumm, Nancy Poı̀ndexter, et al.. (2002). The Protein Product of the Tumor Suppressor Gene, Melanoma Differentiation-Associated Gene 7, Exhibits Immunostimulatory Activity and Is Designated IL-24. The Journal of Immunology. 168(12). 6041–6046. 218 indexed citations

18.

Yu, Tse‐Kuan, et al.. (2000). IL-2 Activation of NK Cells: Involvement of MKK1/2/ERK But Not p38 Kinase Pathway. The Journal of Immunology. 164(12). 6244–6251. 123 indexed citations

19.

Yang, Stephen C., et al.. (1991). Phenotype and Cytolytic Activity of Mouse Tumor-Bearer Splenocytes and Tumor-Infiltrating Lymphocytes from K-1735 Melanoma Metastases Following Anti-CD3, Interleukin-2, and Tumor Necrosis Factor-?? Combination lmmunotherapy. Journal of Immunotherapy. 10(5). 326–335. 6 indexed citations

20.

George, Richard E., William G. Loudon, Richard P. Moser, et al.. (1988). In vitro cytolysis of primitive neuroectodermal tumors of the posterior fossa (medulloblastoma) by lymphokine-activated killer cells. Journal of neurosurgery. 69(3). 403–409. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact